- OncoSil (OSL) treats its first commercial patients with its namesake device at two key treatment centres in the Middle East and Spain
- The treatment took place at the Wolfson Medical Center in Tel Aviv in Israel and the Clinica Universidad de Navarra in Spain
- OSL Managing Director Nigel Lange says the news marks a “significant achievement” for the company
- The OncoSil device is designed to offer cancer patients a more concentrated and localised beta radiation compared to external beam radiation
- Shares in OSL are up 2.38 per cent and trading at 4.3 cents at 1:34 pm AEDT
OncoSil (OSL) has treated its first commercial patients with its namesake device at two key treatment centres in the Middle East and Spain.
The first patient treatment took place at the Wolfson Medical Center in Tel Aviv in Israel. The company said it was continuing to work with other institutions in Israel to treat patients with the device.
The OncoSil device is a targeted radioactive isotope implanted into a patient’s pancreatic tumour through an endoscopic ultrasound. It offers a more concentrated and localised beta radiation compared to external beam radiation.
“It is a significant achievement to treat our first patient in the Middle East and we look forward to providing hope to patients in this region with a poor prognosis from cancer of the pancreas,” OncoSil Managing Director Nigel Lange said.
The other first patient treatment took place at the Clinica Universidad de Navarra in Pamplona, Spain.
OncoSil said the addition of Clinica Universidad de Navarra, a leading private hospital in Spain, as a treatment site would help put the company’s product on the map as a treatment option across Spain and also the rest of Europe.
“We are also pleased with the progress that we continue to make in Spain, which should improve the recognition of the OncoSil device as a treatment option for patients with pancreatic cancer,” Mr Lange said.
Shares in OSL were up 2.38 per cent and trading at 4.3 cents at 1:34 pm AEDT.